Happy Friday!
Did you see Sweet Earth (SE) overnight?
Up to $0.405! Our entry price is $0.20…
We are working on a number of Peak deals in the background and looking forward to sharing them with you.
Across markets…
Australian shares are set to open lower with shares falling in Europe and edging higher in New York as the Biden administration moves to take control of the government.
President Joe Biden is expected to detail a comprehensive pandemic plan on Friday AEDT. It comes as the daily death toll in the US reset its record high.
ASX futures were down 24 points or 0.4 per cent to 6748 near 6.30am AEDT. The currency was little changed.
Shares were higher in afternoon trade in New York. All three major benchmarks were in positive territory; earlier both the Dow and S&P 500 had traded modestly negative.
At 2.40pm the Dow was up 0.1 per cent, pulled higher by a 3.5 per cent gain in Apple. Intel was more than 2 per cent up; it's poised to release quarterly results after the closing bell.
After surging on Wednesday on bullish subscriber data, Netflix was modestly lower, down 1.4 per cent.
Source: AFR
Keeping track of all that’s going on with clinical trials in the sector and on the ASX can be tricky. Until now.
As life sciences investors know, clinicial research is what drives success or failure for biopharmaceutical companies.
Welcome to Stockhead’s inaugural clinical trials tracker – an effort to list the clinical trials underway and planned in the near term for nearly every ASX-listed life sciences company.
As a small-cap publication, we’ve excluded research by CSL (ASX:CSL) from this tracker. Readers interested in the 25 different clinical trials underway by the $122 billion blood products giant can find a list here.
We also don’t include pre-clinical research such as that conducted on animals or human cells in a test tube (in vivo and in vitro tests).
Given its size, Kazia Therapeutics (ASX:KZA), a $160 million Sydney company developing treatments for brain and ovarian cancer, was a standout in our tracker with the amount of research underway.
Sector: Consumer Discretionary
Year: 2019
Deal Type: Placement
Raise Amount: $2.2m
Price Change: $0.046 Unchanged
Sector: Consumer Discretionary
Year: 2018, 2019
Deal Type: Seed, Bridging and IPO
Raise Amount: $10m
Price Change: $0.16 -3.12%
Sector: Technology
Year: 2018
Deal Type: Seed and IPO
Raise Amount: $10m
Price Change: $0.061 Unchanged
Sector: Mining
Year: 2017
Deal Type: Seed & IPO
Raise Amount: $5m
Price Change: $0.22 Unchanged
Sector: Mining
Year: 2017
Deal Type: IPO & Placement
Raise Amount: $6m
Price Change: $0.050 Unchanged
Sector: Healthcare Equipment and Services
Year: 2016
Deal Type: IPO
Raise Amount: $8m
Price Change: $0.12 -14.29%
Sector: Materials
Year: 2016
Deal Type: IPO
Raise Amount: $9m
Price Change: $0.034 +3.03%
Sector: Biotechnology
Year: 2015, 2017, 2018
Deal Type: Placements & IPO
Raise Amount: $5m
Price Change: $2.44 -0.81%
Sector: Media an Entertainment
Year: 2016
Deal Type: Reverse Takeover
Raise Amount: $4m
Price Change: $0.041 -4.65%
Sector: Mining
Year: 2018, 2019, 2020
Deal Type: Placements & Rights Offer
Raise Amount: $1.5m
Price Change: $0.012 +9.09%
Sector: Discretionary
Year: 2020
Deal Type: Placement
Raise Amount: $1.3m
Price Change: $0.066 Unchanged
Sector: Gaming
Year: 2020
Deal Type: Placement
Raise Amount: $1.25m
Price Change: $0.12 Unchanged
Sector: Mining (Gold)
Year: 2020
Deal Type: Placement
Raise Amount: $982k
Sector: Mining (Gold/Silver)
Year: 2020
Deal Type: Placement
Raise Amount: $2.3m
Price Change: $0.012 Unchanged
Sector: Hemp & CBD
Year: 2020
Deal Type: Pre IPO
Raise Amount: $2.5m
Sector: Psychedelic assisted therapy
Year: 2020
Deal Type: Placement
Raise Amount: $2.5m
Price Change: CAD $0.13 Unchanged
Sector: Mining
Year: 2020
Deal Type: Placement
Raise Amount: $330k
Price Change: 0.049 Unchanged
If you would like more information on future Peak deals, please don’t hesitate to get in touch.
